Novel Agents in the
Treatment of Lung Cancer
New Approaches to First-Line Therapies
CME Information
Up to 3.0 AMA PRA Category 1 Credit(s)™
Release date: February 2010 Valid through: January 2011
Course Material: Online Only
Receiving CME Credit
To receive online CME credit for this activity, read the full activity then click below to complete the post-test and evaluation hosted on freeCME.com. You will be able to print your CME certificate immediately following completion of the post-test and evaluation.
Target Audience
This educational activity is intended for oncologists and other medical professionals who assess, treat, and counsel patients with lung cancer.
Learning Objectives
After completing this activity, participants should be able to:
- Discuss considerations in assessing patients presenting with advanced NSCLC.
- Discuss considerations in determining first-line treatment options for patients presenting with advanced NSCLC.
- Discuss considerations in integrating supportive care and managing brain metastasis in treatment strategies for patients with advanced NSCLC.
- Implement appropriate treatment and supportive care strategies into practice in assessing, counseling and treating patients with advanced NSCLC.
Educational Need
Results of important recent clinical studies of first-line EGFR TKI therapies, antibodies combined with chemotherapy, consolidation and up-front supportive care are creating the potential to change the paradigm for what constitutes appropriate first-line care for non–small cell lung cancer (NSCLC) patients. Medical professionals who work with lung cancer patients need to understand the results of these new studies assess their implications for the management of NSCLC and integrate this information into their practice of assessing, counseling and treating individual patients.
Companion CME Activity
A companion CME activity, Lung Cancer: Case Studies Assessing Novel Agents in First-Line Therapy, based on videotaped discussion of cases is available at First-Line Case Studies. The activity provides more in-depth information on this topic, featuring an overview by Thomas J. Lynch, Jr, MD, and discussion of 4 cases by the same program faculty that developed this activity. The activity offers up to 2 additional AMA PRA Category 1 Credits™.
Program Faculty
Thomas J. Lynch, Jr, MD
Director, Yale Cancer Center
Physician-in-Chief Smilow Cancer Center at Yale – New Haven
New Haven, Connecticut
Tracy T. Batchelor, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Tracey Evans, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Panos Fidias, MD
Massachusetts General Hospital
Center for Thoracic Cancers
Boston, Massachusetts
Glenwood D. Goss, MD, FCPSA, FRCPC
Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Nasser H. Hanna, MD
Indiana University School of Medicine
Indianapolis, Indiana
Daniel D. Karp, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Natasha Leighl, MD, MMSc, FRCPC
Princess Margaret Hospital
Toronto, Ontario, Canada
Lecia V. Sequist, MD, MPH
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Jennifer Temel, MD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Sponsorship and Accreditation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.
Educational Grant Support
The program is supported by educational grants provided by Bristol-Myers Squibb and ImClone Systems Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech.
Credit Designation
InforMEDical designates this continuing medical education activity for up to 2 AMA PRA Category 1 Credits™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.
Financial Disclosures
Tracy T. Batchelor: Consultant: Acceleron, ImClone, EMD-Serono, Exelixis; Research Funding: AstraZeneca, Millennium, Schering-Plough. Tracey L. Evans: Consultant: Bristol-Myers Squibb; Speakers’ Bureau: Eli Lilly, Genentech. Glenwood D Goss: Honoraria: AstraZeneca, Hoffman-La Roche; Research Funding: AstraZeneca, Hoffman-La Roche. Nasser H. Hanna: Honoraria: Celgene, Merck. Daniel D. Karp: Research Funding: Pfizer. Natasha B. Leighl: Honoraria: Bristol-Myers Squibb. Thomas J. Lynch, Jr: Consultant: AstraZeneca, Boehringer Ingelheim, Hoffman-La Roche, Merck; Patents: Genzyme for EGFR testing; Stock: Biogen. Board of Directors/Stock: Infinity Pharmaceuticals. Lecia V Sequist: Nothing to disclose. Jennifer Temel: Nothing to disclose. CME Reviewers: Nothing to disclose. InforMEDical: Melinda Lindquist: Nothing to disclose. Larry Rosenberg: Spouse employed by Bristol-Myers Squibb.
This educational activity may contain discussion of published and/or investigational uses of agents, devices or diagnostics tools that have not been approved for use by the US FDA. The opinions expressed in the activity are those of the authors, and do not reflect those of the industry supporters or CME sponsor. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Participants/readers should appraise the information presented critically and are encouraged to consult appropriate resources for any product, device or diagnostic tool mentioned in this activity.